Entera Bio Ltd.
ENTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Apr 27, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 2, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 13, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 8, 2023 |
| HC Wainwright & Co. | maintain | Buy | Apr 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 28, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 6, 2022 |
| B. Riley Securities | maintain | Buy | Jul 19, 2022 |
| B. Riley Securities | maintain | Buy | Jun 16, 2021 |
| Aegis Capital | maintain | Buy | Mar 22, 2021 |
| Maxim Group | maintain | Buy | Aug 3, 2018 |
Earnings History
Next report: Mar 26, 2027 · EPS est. $-0.15| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-0.11 | $-0.07 | — | — |
| Aug 7, 2026 | $-0.14 | $-0.08 | — | — |
| May 8, 2026 | $-0.07 | $-0.08 | — | — |
| Mar 27, 2026 | $-0.07 | $-0.09 | — | — |
| Nov 14, 2025 | $-0.07 | $-0.09 | — | — |
| Aug 8, 2025 | $-0.06 | $-0.11 | — | — |
| May 9, 2025 | $-0.06 | $-0.07 | $42.0K | — |
| Mar 28, 2025 | $-0.06 | $-0.08 | $82.0K | $40.0K |
News
Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026
TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinical leader Juan Camilo Arjona Ferreira, M.D., to its Board of Directors, effective December 1, 2026. Dr. Arjona Ferreira will succeed Ms. Haya Taitel, who is stepping down from the Board.
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia)
TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Conv…
TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026.
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences:
TEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in the following upcoming fall investor conferences: 2026 Cantor Global Healthcare Conference Fireside Chat: September 10, 2026 at 1:00 p.m.
Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens Entera's clinical execution team and late-stage development capabilities ahead of planned EB613 Phase 3 initiation TEL AVIV, Israel, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appoint…
Entera Bio NASDAQ: ENTX plans to begin a Phase 3 study of its oral osteoporosis candidate EB613 after reaching agreement with the U.S. Food and Drug Administration on a 12-month, placebo-controlled registrational trial, Chief Executive Officer Miranda Toledano said during a discussion hosted by Canaccord Genuity.